These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9842009)

  • 1. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction.
    Lorenzoni R; Gistri R; Cecchi F; Olivotto I; Chiriatti G; Elliott P; McKenna WJ; Camici PG
    Am Heart J; 1998 Dec; 136(6):972-81. PubMed ID: 9842009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary vasodilator reserve in primary and secondary left ventricular hypertrophy. A study with positron emission tomography.
    Choudhury L; Rosen SD; Patel D; Nihoyannopoulos P; Camici PG
    Eur Heart J; 1997 Jan; 18(1):108-16. PubMed ID: 9049522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a
    Sciagrà R; Calabretta R; Cipollini F; Passeri A; Castello A; Cecchi F; Olivotto I; Pupi A
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):866-875. PubMed ID: 28050630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy.
    Olivotto I; Cecchi F; Gistri R; Lorenzoni R; Chiriatti G; Girolami F; Torricelli F; Camici PG
    J Am Coll Cardiol; 2006 Mar; 47(5):1043-8. PubMed ID: 16516091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypertrophic non-obstructive cardiomyopathy assessed by dipyridamole thallium single photon emission computed tomography: comparisons with hypertrophic cardiomyopathy with a dilated heart].
    Mori T; Suda K; Ohnishi M; Kanoh Y; Shiotani H; Yokota Y; Fujitani K; Fukuzaki H; Maeda K
    J Cardiol; 1987 Mar; 17(1):35-46. PubMed ID: 3501444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.
    Cecchi F; Olivotto I; Gistri R; Lorenzoni R; Chiriatti G; Camici PG
    N Engl J Med; 2003 Sep; 349(11):1027-35. PubMed ID: 12968086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function.
    Lorenzoni R; Gistri R; Cecchi F; Olivotto I; Chiriatti G; Elliott P; McKenna WJ; Camici PG
    Eur Heart J; 1997 Dec; 18(12):1946-50. PubMed ID: 9447323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy.
    van den Heuvel AF; van Veldhuisen DJ; van der Wall EE; Blanksma PK; Siebelink HM; Vaalburg WM; van Gilst WH; Crijns HJ
    J Am Coll Cardiol; 2000 Jan; 35(1):19-28. PubMed ID: 10636254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment.
    Choudhury L; Elliott P; Rimoldi O; Ryan M; Lammertsma AA; Boyd H; McKenna WJ; Camici PG
    Basic Res Cardiol; 1999 Feb; 94(1):49-59. PubMed ID: 10097830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systolic function reserve using two-dimensional strain imaging in hypertrophic cardiomyopathy: comparison with essential hypertension.
    Badran HM; Faheem N; Ibrahim WA; Elnoamany MF; Elsedi M; Yacoub M
    J Am Soc Echocardiogr; 2013 Dec; 26(12):1397-406. PubMed ID: 24094559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy.
    Bravo PE; Pinheiro A; Higuchi T; Rischpler C; Merrill J; Santaularia-Tomas M; Abraham MR; Wahl RL; Abraham TP; Bengel FM
    J Nucl Med; 2012 Mar; 53(3):407-14. PubMed ID: 22315440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography.
    Camici P; Chiriatti G; Lorenzoni R; Bellina RC; Gistri R; Italiani G; Parodi O; Salvadori PA; Nista N; Papi L
    J Am Coll Cardiol; 1991 Mar; 17(4):879-86. PubMed ID: 1999624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy.
    Bravo PE; Pozios I; Pinheiro A; Merrill J; Tsui BM; Wahl RL; Bengel FM; Abraham MR; Abraham TP
    Am J Cardiol; 2012 Oct; 110(7):1033-9. PubMed ID: 22748357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy.
    Timmer SA; Knaapen P; Germans T; Dijkmans PA; Lubberink M; Ten Berg JM; Ten Cate FJ; Rüssel IK; Götte MJ; Lammertsma AA; van Rossum AC
    Am J Physiol Heart Circ Physiol; 2011 Jul; 301(1):H129-37. PubMed ID: 21490327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of left ventricular systolic and diastolic abnormalities in patients with hypertrophic cardiomyopathy using real-time three-dimensional echocardiography and two-dimensional speckle tracking imaging.
    Huang X; Yue Y; Wang Y; Deng Y; Liu L; Di Y; Sun S; Chen D; Fan L; Cao J
    Cardiovasc Ultrasound; 2018 Oct; 16(1):23. PubMed ID: 30285887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations.
    Olivotto I; Girolami F; Sciagrà R; Ackerman MJ; Sotgia B; Bos JM; Nistri S; Sgalambro A; Grifoni C; Torricelli F; Camici PG; Cecchi F
    J Am Coll Cardiol; 2011 Aug; 58(8):839-48. PubMed ID: 21835320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow-function relation in patients with chronic coronary artery disease and reduced regional function. A positron emission tomographic and two-dimensional echocardiographic study with coronary vasodilator stress.
    Torres MA; Picano E; Parodi G; Sicari R; Veglia F; Giorgetti A; Marzullo P; Parodi O
    J Am Coll Cardiol; 1997 Jul; 30(1):65-70. PubMed ID: 9207622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography.
    Neglia D; Parodi O; Gallopin M; Sambuceti G; Giorgetti A; Pratali L; Salvadori P; Michelassi C; Lunardi M; Pelosi G
    Circulation; 1995 Aug; 92(4):796-804. PubMed ID: 7641359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal.
    Castagnoli H; Ferrantini C; Coppini R; Passeri A; Baldini K; Berti V; Cecchi F; Olivotto I; Sciagrà R
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2413-2422. PubMed ID: 27527796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial blood flow and fibrosis in hypertrophic cardiomyopathy.
    Aquaro GD; Todiere G; Barison A; Strata E; Marzilli M; Pingitore A; Lombardi M
    J Card Fail; 2011 May; 17(5):384-91. PubMed ID: 21549295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.